<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04051463</url>
  </required_header>
  <id_info>
    <org_study_id>2019-007</org_study_id>
    <nct_id>NCT04051463</nct_id>
  </id_info>
  <brief_title>Rhopressa for Corneal Edema Associated With Fuchs Dystrophy</brief_title>
  <official_title>Prospective Randomized Study to Determine Whether Use of Rhopressaâ„¢ Can Ameliorate Corneal Edema Associated With Fuchs Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Price Vision Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Price Vision Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to determine whether use of Rhopressa improves the ability of corneal
      endothelial cells to maintain appropriate corneal hydration in patients with Fuchs
      endothelial corneal dystrophy (FECD), which could help delay or prevent the need for a
      corneal transplant.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 5, 2019</start_date>
  <completion_date type="Actual">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The active drug and placebo will be provided in 2.5 ml bottles identical, in appearance. Only the designated dosing coordinator is unmasked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Central corneal thickness</measure>
    <time_frame>1 month</time_frame>
    <description>Central corneal thickness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corrected distance visual acuity</measure>
    <time_frame>3 months</time_frame>
    <description>Corrected distance visual acuity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Fuchs Endothelial Dystrophy</condition>
  <arm_group>
    <arm_group_label>Netarsudil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A drop of Netarsudil 0.02% ophthalmic solution will be instilled into both eyes once daily at night.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo eye drop, consisting of the vehicle for netarsudil ophthalmic solution without the active ingredient, will be instilled into both eyes once daily at night.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Netarsudil Ophthalmic Solution</intervention_name>
    <description>Netarsudil eye drops instilled once daily</description>
    <arm_group_label>Netarsudil</arm_group_label>
    <other_name>Rhopressa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo eye drops instilled once daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Rhopressa vehicle without active ingredient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Male or female patient diagnosed with FECD and corneal edema evident by slit lamp exam
             and/or corneal tomography.

          -  Patient is able and willing to administer eye drops.

          -  Patient is able to comprehend and has signed the Informed Consent form.

        Exclusion Criteria:

          -  Active intraocular inflammation, corneal ulceration, keratitis, or conjunctivitis.

          -  Known sensitivity to any of the ingredients in the study medications.

          -  Abnormal eyelid function.

          -  History of herpetic keratitis.

          -  History of non-compliance with using prescribed medication.

          -  Current or planned pregnancy within the study duration.

          -  Concurrent involvement or participation in another randomized clinical trial within 30
             days prior to enrollment in this study.

          -  Any ocular or systemic condition (i.e., UNCONTROLLED systemic disease) or situation
             which in the investigator's opinion may put the patient at significant risk, confound
             the study results, or interfere significantly with the patient's participation in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis W Price, Jr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Price Vision Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Price Vision Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 7, 2019</study_first_submitted>
  <study_first_submitted_qc>August 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fuchs' Endothelial Dystrophy</mesh_term>
    <mesh_term>Corneal Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

